Neurocrine Biosciences Inc (NASDAQ: NBIX), a neuroscience-focused, biopharmaceutical company, announced on Tuesday, that it has reported its financial results for the fourth quarter of 2019.
The company reported GAAP net income and diluted earnings per share of USD34m and USD0.35 respectively in the fourth quarter of 2019, compared to USD18m and USD0.19 respectively in the same period in 2018.
The firm posted non-GAAP net income and diluted earnings per share at USD102m and USD1.05 respectively in the fourth quarter of 2019, as against USD38m and USD0.40 for the same period in 2018.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development